Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objective: The aim of this study was to report on the clinical efficacy and side effects of aripiprazole in treating behavioral symptoms of children with a developmental disability (DDs). Design/methods: A retrospective chart review of the first 32 children treated with aripiprazole at an urban clinic for children with DD was conducted. Results: Ages ranged from 5 to 19 years; 9 (28%) were female. Twenty four had diagnoses within the autistic spectrum and 18 had mental retardation (MR). Other disorders included: attention-deficit/hyperactivity disorder/disruptive behavior disorders (n = 13), mood disorders (n = 7), reactive attachment (n = 2), and sleep disorders (n = 2). Target symptoms included aggression, hyperactivity, impulsivity and, self-injurious behaviors. Twenty eight of the children were switched from another antipsychotic. The mean daily aripiprazole starting dose was 7.1 ± 0.32 mg (0.17 mg/kg/day) and the mean daily maintenance dose was 10.55 ± 6.9 mg (0.27 mg/kg/day). Aripiprazole had been used for a period between 6 and 15 months. Improvement in target symptoms was found in 56%. When treating a child with MR, the concomitant presence of an autistic spectrum diagnosis predicted a worse outcome. Side effects were reported in 16 (50%), with the most frequent being sleepiness (n = 6). Mean body mass index (BMI) rose from 22.5 to 24.1 (p = 0.003) over the follow up period, with changes in the BMI z scores. These changes were more pronounced in children younger than 12 years. Conclusions: These results with aripiprazole in this difficult-to-treat population suggest that this medication warrants controlled studies of its effectiveness and safety.

Original languageEnglish (US)
Pages (from-to)549-560
Number of pages12
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number5
DOIs
StatePublished - Oct 2006

Fingerprint

Off-Label Use
Developmental Disabilities
Intellectual Disability
Body Mass Index
Attention Deficit and Disruptive Behavior Disorders
Self-Injurious Behavior
Behavioral Symptoms
Impulsive Behavior
Disabled Children
Attention Deficit Disorder with Hyperactivity
Aggression
Mood Disorders
Antipsychotic Agents
Aripiprazole
Safety
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{4796fcce8a924ab593c01e1ee6f8a7ef,
title = "Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities",
abstract = "Objective: The aim of this study was to report on the clinical efficacy and side effects of aripiprazole in treating behavioral symptoms of children with a developmental disability (DDs). Design/methods: A retrospective chart review of the first 32 children treated with aripiprazole at an urban clinic for children with DD was conducted. Results: Ages ranged from 5 to 19 years; 9 (28{\%}) were female. Twenty four had diagnoses within the autistic spectrum and 18 had mental retardation (MR). Other disorders included: attention-deficit/hyperactivity disorder/disruptive behavior disorders (n = 13), mood disorders (n = 7), reactive attachment (n = 2), and sleep disorders (n = 2). Target symptoms included aggression, hyperactivity, impulsivity and, self-injurious behaviors. Twenty eight of the children were switched from another antipsychotic. The mean daily aripiprazole starting dose was 7.1 ± 0.32 mg (0.17 mg/kg/day) and the mean daily maintenance dose was 10.55 ± 6.9 mg (0.27 mg/kg/day). Aripiprazole had been used for a period between 6 and 15 months. Improvement in target symptoms was found in 56{\%}. When treating a child with MR, the concomitant presence of an autistic spectrum diagnosis predicted a worse outcome. Side effects were reported in 16 (50{\%}), with the most frequent being sleepiness (n = 6). Mean body mass index (BMI) rose from 22.5 to 24.1 (p = 0.003) over the follow up period, with changes in the BMI z scores. These changes were more pronounced in children younger than 12 years. Conclusions: These results with aripiprazole in this difficult-to-treat population suggest that this medication warrants controlled studies of its effectiveness and safety.",
author = "Valicenti-McDermott, {Maria D.R.} and Howard Demb",
year = "2006",
month = "10",
doi = "10.1089/cap.2006.16.549",
language = "English (US)",
volume = "16",
pages = "549--560",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities

AU - Valicenti-McDermott, Maria D.R.

AU - Demb, Howard

PY - 2006/10

Y1 - 2006/10

N2 - Objective: The aim of this study was to report on the clinical efficacy and side effects of aripiprazole in treating behavioral symptoms of children with a developmental disability (DDs). Design/methods: A retrospective chart review of the first 32 children treated with aripiprazole at an urban clinic for children with DD was conducted. Results: Ages ranged from 5 to 19 years; 9 (28%) were female. Twenty four had diagnoses within the autistic spectrum and 18 had mental retardation (MR). Other disorders included: attention-deficit/hyperactivity disorder/disruptive behavior disorders (n = 13), mood disorders (n = 7), reactive attachment (n = 2), and sleep disorders (n = 2). Target symptoms included aggression, hyperactivity, impulsivity and, self-injurious behaviors. Twenty eight of the children were switched from another antipsychotic. The mean daily aripiprazole starting dose was 7.1 ± 0.32 mg (0.17 mg/kg/day) and the mean daily maintenance dose was 10.55 ± 6.9 mg (0.27 mg/kg/day). Aripiprazole had been used for a period between 6 and 15 months. Improvement in target symptoms was found in 56%. When treating a child with MR, the concomitant presence of an autistic spectrum diagnosis predicted a worse outcome. Side effects were reported in 16 (50%), with the most frequent being sleepiness (n = 6). Mean body mass index (BMI) rose from 22.5 to 24.1 (p = 0.003) over the follow up period, with changes in the BMI z scores. These changes were more pronounced in children younger than 12 years. Conclusions: These results with aripiprazole in this difficult-to-treat population suggest that this medication warrants controlled studies of its effectiveness and safety.

AB - Objective: The aim of this study was to report on the clinical efficacy and side effects of aripiprazole in treating behavioral symptoms of children with a developmental disability (DDs). Design/methods: A retrospective chart review of the first 32 children treated with aripiprazole at an urban clinic for children with DD was conducted. Results: Ages ranged from 5 to 19 years; 9 (28%) were female. Twenty four had diagnoses within the autistic spectrum and 18 had mental retardation (MR). Other disorders included: attention-deficit/hyperactivity disorder/disruptive behavior disorders (n = 13), mood disorders (n = 7), reactive attachment (n = 2), and sleep disorders (n = 2). Target symptoms included aggression, hyperactivity, impulsivity and, self-injurious behaviors. Twenty eight of the children were switched from another antipsychotic. The mean daily aripiprazole starting dose was 7.1 ± 0.32 mg (0.17 mg/kg/day) and the mean daily maintenance dose was 10.55 ± 6.9 mg (0.27 mg/kg/day). Aripiprazole had been used for a period between 6 and 15 months. Improvement in target symptoms was found in 56%. When treating a child with MR, the concomitant presence of an autistic spectrum diagnosis predicted a worse outcome. Side effects were reported in 16 (50%), with the most frequent being sleepiness (n = 6). Mean body mass index (BMI) rose from 22.5 to 24.1 (p = 0.003) over the follow up period, with changes in the BMI z scores. These changes were more pronounced in children younger than 12 years. Conclusions: These results with aripiprazole in this difficult-to-treat population suggest that this medication warrants controlled studies of its effectiveness and safety.

UR - http://www.scopus.com/inward/record.url?scp=33750943235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750943235&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.549

DO - 10.1089/cap.2006.16.549

M3 - Article

C2 - 17069544

AN - SCOPUS:33750943235

VL - 16

SP - 549

EP - 560

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -